Exact Sciences (EXAS) Enrolls First Patient in Pivotal MCED Study

Exact Sciences Corporation (EXAS) recently enrolled the first patient in its pivotal Multi-Cancer Early Detection (“MCED”) Falcon Registry Real-World Evidence (“RWE”) study. The Texas-based not-for-profit health system, Baylor Scott & White, will serve as the principal site for the study, with Endeavor Health in Chicago set to begin enrolling patients this fall.The multi-site study will register up to 25,000 patients, evaluating the clinical performance, patient and provider experience, and psychological im ...